Waldenström's macroglobulinemia. Current developments in diagnostics and therapy

Der Internist
A Grunenberg, C Buske

Abstract

Waldenström's macroglobulinemia (WM) is a rare subclass of the group of indolent B-cell lymphomas representing only 1-2 % of all hematological neoplasms. Genetic characterization of the disease allows a subdivision of WM into genotypes. The combination of rituximab and chemotherapy is still the backbone of treatment. The proteasome inhibitor bortezomib is another effective treatment option. The newly introduced oral Bruton's tyrosine kinase inhibitor ibrutinib provides an effective chemotherapy-free therapy for WM.

References

Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios Athanasios DimopoulosGerasimos Pangalis
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irene M GhobrialJeffrey Matous
Mar 10, 2011·British Journal of Haematology·Sigbjørn Berentsen
Aug 30, 2011·Bone Marrow Transplantation·M A GertzS M Ansell
Aug 31, 2012·The New England Journal of Medicine·Steven P TreonZachary R Hunter
Feb 7, 2013·Leukemia·C Buske, V Leblond
Jun 19, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Lucy S Hodge, Stephen M Ansell
Aug 1, 2013·Current Oncology Reports·Jorge MongeStephen M Ansell
Oct 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BuskeUNKNOWN ESMO Guidelines Working Group
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles
Jul 26, 2014·Blood·Enrica Morra
Apr 9, 2015·The New England Journal of Medicine·Steven P TreonRanjana H Advani
May 24, 2015·Blood·Steven P Treon

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Nederlands tijdschrift voor geneeskunde
Baart de la Faille-Kuyp
Folia haematologica; internationales Magazin für Blutforschung
U KANZOW, H SCHULTEN
© 2021 Meta ULC. All rights reserved